CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 32 enrolled
Drug / intervention
Tobacco product administration and assessmentother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05971823
NCT05971823N/ACompleted

Effects of Electronic Cigarette Flavors on Abuse Liability in Smokers (P3-Taste)

Virginia Commonwealth University·interventional·Posted Aug 2, 2023·Updated Apr 6, 2026

In Brief

A clinical study evaluating Tobacco product administration and assessment for Electronic Cigarette Use. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if abuse liability indices will be impacted by varying flavors and e-cigarette (ECIG) nicotine delivery capability (i.e., nicotine flux) among current combustible cigarette users. The investigators will compare abuse liability indices between three FDA-authorized ECIG products that vary in nicotine flux (but are all tobacco flavor) and own brand cigarettes. The investigators will also test the influence of ECIG flavor availability (tobacco vs. menthol) within three ECIG product classes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
202420252026
First PostedAug 2, 2023
Enrollment StartJul 31, 2023
Primary CompletionJul 26, 2024
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 2.9 years ago

Interventions

Tobacco product administration and assessmentother

Subjective measures 1 is followed by product sampling that includes 5 self-directed ECIG/own brand cigarette puffs over 10 minutes. After sampling is complete participants complete subjective measures 2. Ten minutes after their sampling has been completed, they complete subjective measures 3 and the behavioral economic task(s). These activities are preceded and followed by cardiovascular response assessment.